Table 4 Univariate analysis of independent determinant of ≥ 50% response
< 50% response | > 50% response | P-value | |
|---|---|---|---|
Patients, n (%) | 19 (35.8) | 34 (64.2) | - |
Age, yrs, mean ± SD | 53.8 ± 9.4 | 44.3 ± 11.3 | 0.03 |
Females, n (%) | 14 (34.1) | 27 (65.9) | ns |
BMI, mean ± SD | 24.4 ± 3.9 | 23.7 ± 3.5 | ns |
Age at CM onset, mean ± SD | 37.2 ± 15.4 | 31.9 ± 11.2 | ns |
Disease duration, mean ± SD | 31.5 ± 15.0 | 28.5 ± 13.3 | ns |
MMDs/MHDs at baseline, mean ± SD | 18.9 ± 6.3 | 15.9 ± 6.0 | ns |
NRS score, mean ± SD | 8.6 ± 1.3 | 8.5 ± 1.0 | ns |
Pain location, n (%) | ns | ||
Unilateral | 8 (44.4) | 13 (44.8) | |
Unilateral, bilateral | 8 (44.4) | 15 (51.7) | |
Bilateral | 2 (11.2) | 1 (3.5) | |
Pain quality, n (%) | ns | ||
Pulsating | 9 (56.3) | 19(57.6) | |
Pressing/tightening | 6 (37.5) | 6 (18.2) | |
Other | 1 (6.2) | 8 (24.2) | |
UAs, n (%) | 9 (56.3) | 24 (72.7) | ns |
Allodynia, n (%) | 10 (62.5) | 19 (57.6) | ns |
Dopaminergic symptoms, n (%) | 10 (62.5) | 20 (60.6) | ns |
MAI at baseline, mean ± SD | 25.7 ± 17.3 | 15.3 ± 15.0 | 0.026 |
MO, n (%) | 13 (86.7) | 18 (85.7) | ns |
Duration of MO, months; mean ± SD | 40.4 ± 49.5 | 13.8 ± 12.1 | 0.041 |
Triptan responders, n (%) | 12 (63.2) | 22 (64.7) | ns |
Pts using concomitant prophylaxis, n (%) | 11 (57.9) | 18 (52.9) | ns |
Tricyclics | 4 (36.4) | 6 (33.3) | |
Anticonvulsants | 3 (27.3) | 3 (16.7) | |
Calcium-antagonists | 0 | 1 (5.6) | |
Serotoninergic antagonists | 1 (9.1) | 4 (22.2) | |
Beta-blockers | 3 (27.3) | 6 (33.3) | |
BoNT/A | 0 | 2 (11.1) | |
Other | 2 (18.2) | 4 (22.2) | |
Prior treatment failures, mean ± SD | 5.1 ± 3.1 | 4.1 ± 1.5 | ns |
1–2 | 2 (10.5) | 2 (6.5) | |
3–4 | 9 (47.4) | 21 (63.6) | |
> 4 | 8 (42.1) | 8 (24.2) | |
Response to BoNT/A, n (%) | 4 (50.0) | 7 (70.0) | ns |
Pts with ≥ 1 comorbidity, n (%) | 11 (32.4) | 23 (67.6) | ns |
Pts with psychiatric comorbidities, n (%) | 3 (15.8) | 7(21.2) | ns |
HIT-6 score at baseline, mean ± SD | 69.1 ± 4.1 | 62.7 ± 21.5 | ns |
MIDAS score at baseline, mean ± SD | 93.7 ± 42.0 | 86.9 ± 52.9 | ns |
Fremanezumab dosing regimen, n (%) | |||
Monthly | 11 (57.9) | 33 (97.1) | 0.001 |
Quarterly | 8 (42.1) | 1 (2.9) | |